spacer
home > ebr > summer 2018 > gene therapy
PUBLICATIONS
European Biopharmaceutical Review

Gene Therapy

In 2014, following a quarter of a century roller coaster trajectory, Ledley et al published very optimistic conclusions after their examination of life cycles of gene therapy, stating “Gene therapy technologies are now achieving the level of maturity that innovation research and biotechnology experience suggest may be requisite for efficient product development” (1). Looking at the following, it seems that reality meets those odds:

• The first marketing authorisations granted in the Western countries (Strimvelis® for the rare immunodeficiency syndrome adenosine-deaminase-severe combined immunodeficiency (ADA-SCID), Imlygic® [HSV1-GMCSF] for melanoma, Kymriah® for acute leukocytic leukemia, Yescarta® for non-Hodgkin lymphoma, Luxturna® for Leber congenital amaurosis)
• The steady maturation of the field since the 1980s (>40,000 papers, nearly 20,000 patents, >2,500 clinical trials including >100 late stage Phase 2/3 or Phase 3 trials)
• Billions in capital investments and initial public offerings (IPOs) in gene therapy companies, the activity being now driven by large pharmaceutical companies (with a peak reached recently with the $8.7 billion acquisition of Avexis by Novartis)

Gene therapy is defined as the introduction of genetic material into patients with an intended curative, life-extending, or life-enhancing therapeutic benefit. The applications rely on a myriad of possibilities, including the transient or permanent genetic modification of the administered product or ex vivo-engineered tissue to produce proteins for internal, local, or systemic use, helping to replace or correct faulty genes (in the case of rare diseases), providing stimuli to regenerate tissues (in the case of brain or cardiac disorders), killing tissues, or enhancing defence mechanisms (in the case of cancer or infectious diseases).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Serge Braun PharmD, PhD, is Scientific Director of AFM-Téléthon, President of Genosafe (a CRO company dedicated to quality control of biotherapeutic products) and Director Neuromuscular diseases at Généthon. He has 10 years of experience in the neuromuscular diseases field in the academic sector and 10 years in the biotech sector as Vice President of Research of Transgene SA. Serge was also co-founder of Neurofit, a CRO specialised in preclinical testings, and Vice President of Alsace BioValley, the non-profit making organisation for the development of a major biotech cluster in Europe. He also serves as advisor for Venture Capital companies and bioclusters.
spacer
Dr Serge Braun
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Get on Board with a Neat Idea

Teknomek has launched a new range of anti-microbial shadow boards developed to meet the specific needs of the pharma sector. The products are made from PVC infused with Biomaster anti-bacterial silver-ion technology, which inhibits the growth of bacteria by up to 99.9%.
More info >>

White Papers

New Temperature Profiles from a Global Study

Laminar Medica

Recently there has been an influx of temperature mapping studies to collect sufficient ambient data to develop temperature profiles.  Solid temperature profiles on specific shipping routes are required to ensure streamlined packaging and robust lane qualification. The most reliable method to develop temperature profiles is to capture the actual reading from shipments, as well as using the historical and meteorological data to increase the confidence level.
More info >>

 
Industry Events

PPMA SHOW 2018

25-27 September 2018, NEC, Birmingham, UK

The UK’s leading production line event is celebrating its 30th Anniversary. Taking place at the NEC, Birmingham from 25-27 September 2018, the exhibition showcases the latest processing and packaging machinery. Attended by thousands of manufacturers of food, pharmaceuticals and FMCG as well as contract packers and more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement